Survey of antibiogram tests in cholera patients in the 2005 epidemic in Hamadan, Islamic Republic of Iran

An analytical cross-sectional study determined the serogroups and serotypes of Vibrio cholerae, and their antibiotic resistance rates, in the 2005 cholera epidemic in Hamadan. All 190 patients with positive stool cultures had V. cholerae serogroup O1, biotype El Tor and serotype Inaba positive. Of 60 cases selected randomly for antibiogram testing, sensitivity to norfloxacin, ciprofloxacin, kanamycin, amikacin, tetracycline and doxycycline was 97%, 92%, 88%, 85%, 77% and 67% respectively. Resistance to furazolidone, trimethoprim-sulfamethoxazole and erythromycin was 100%, 98% and 62% respectively. Comparison with the results of the 1998 epidemic suggests a worrying increase in the resistance of V. cholerae to erythromycin, doxycycline and ciprofloxacin

[Frequency of hepatitis A virus antibodies in patients with hepatitis B and hepatitis C in Iran]

Superinfection of hepatitis A in chronic hepatitis B and C may worsen the course of disease. This study attempted to study frequency of hepatitis A virus antibodies in patients with hepatitis B and hepatitis C. 115 hepatitis C and 56 hepatitis B patients who visited the Hepatitis Association of Hamedan province during 2004-2005 were enrolled. Hepatitis A virus antibodies [IgM, IgG] by ELISA, WBC, hemoglobin, platelet, AST and ALT were evaluated. 32 patients with hepatitis B and 39 patients with hepatitis C refused the study. In 71 [85.5%] patients with hepatitis B, IgG-HAV-Ab and in one patient IgM-HAV-Ab was detected. 36 [92.3%] patients with hepatitis C had IgG-anti-HAV. Due to high frequency of HAV Ab, it is preferable to evaluate patients with hepatitis B and C for HAV-Ab instead of vaccination of all patients

prevalence of chlamydia trachomatis infection by molecular analysis of urine samples in women attending OB and GYN clinics in Tehran

Chlamydia trachomatis is a common and curable STI which can be symptomatic or asymptomatic. Nowadays, PCR is a very sensitive diagnostic tool for detecting Chlamydia in urine and can be used in routine screening procedures as a noninvasive test. There are few studies on the prevalence of C. trachomatis in Iranian women and most of them have small sample sizes which are not suitable for epidemiological deductions. The aim of this study was to estimate the prevalence of urogenital C. trachomatis infections by PCR on urine samples of women in their fertility years and to evaluate the necessity of screening for asymptomatic infections in Iranian women. This WHO supported descriptive-analytical and cross-sectional study was performed on 1052, 15-49 year-old women. Participants were selected randomly from attendees of 5 Obstetric-Gynecologic clinics in Tehran during summer and fall of 2003. The research material consisted of a questionnaire and urine samples which were transported to Avesina Research Institute daily to extract their DNA and prepare them for PCR tests. The gathered data were analyzed by SPSS, version 11, and evaluated statistically by t-test, Chi-square, variance analysis and logistic regression, while considering p<0.05 as significant. The mean age of participants was 28.52 +/- 6.36 years. 56.2% of them had high school education, 94.2% were married, 91.8% were housewives, 32.5% were pregnant, 93.8% were sexually active, 99% of them were monogamous and 48.1% were on contraceptive methods. Among sexually active and non-pregnant participants, 10.4% were taking OCPs, 8.7% were using condoms, 16.3% had IUDs and the rest were on other contraceptive methods. In their reproductive history, 39% had vaginal discharges, 12.9% pelvic pains, 1% ectopic pregnancies, 21.2% abortions, 6.5% premature deliveries, 2.7% low birth weight infants and 7.2% were infertile. 129 subjects, [12.3%], had positive PCR tests. Statistically, there was no significant relationship between subjects, reproductive and personal histories of the subjects with the test results. Based on the estimated prevalence, it seems that chlamydial infection is prevalent in the studied population. In populations with prevalences higher than 4%, screening programs are recommended, so that Chlamydia screening can be considered as a part of health care programs in Iran to reduce the burden of the disease